Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 12 (December)

1. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
   J Natl Cancer Inst, 99(23): 1811-4. [Abstract] [Full-text]
2. Projecting individualized absolute invasive breast cancer risk in African American women.
   J Natl Cancer Inst, 99(23): 1782-92. [Abstract] [Full-text]
3. Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer.
   Cancer Invest, 25(8): 720-5. [Abstract] [Full-text]
4. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review.
   Lancet Oncol, 8(12): 1129-38. [Abstract] [Full-text]
5. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.
   Lancet Oncol, 8(12): 1101-15. [Abstract] [Full-text]
6. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence.
   Lancet Oncol, 8(12): 1088-100. [Abstract] [Full-text]
7. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
   Lancet Oncol, 8(12): 1079-87. [Abstract] [Full-text]
8. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
   Lancet Oncol, 8(12): 1071-8. [Abstract] [Full-text]
9. Early life events and conditions and breast cancer risk: from epidemiology to etiology.
   Int J Cancer, 122(3): 481-5. [Abstract] [Full-text]
10. A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women.
    Int J Cancer, 122(3): 705-10. [Abstract] [Full-text]
11. Organised mammography screening reduces breast cancer mortality: a cohort study from Finland.
    Int J Cancer, 122(3): 614-9. [Abstract] [Full-text]
12. Nutrient dietary patterns and the risk of breast and ovarian cancers.
    Int J Cancer, 122(3): 609-13. [Abstract] [Full-text]
13. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.
    J Clin Oncol, 25(35): 5584-90. [Abstract] [Full-text]
14. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy.
    J Clin Oncol, 25(35): 5591-6. [Abstract] [Full-text]
15. Detecting high-order interactions of single nucleotide polymorphisms using genetic programming.
    Bioinformatics, 23(24): 3280-8. [Abstract] [Full-text]
16. Herceptin.
    Handb Exp Pharmacol. [Abstract] [Full-text]
17. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition.
    Oncogene, 26(57): 7859-71. [Abstract] [Full-text]
18. Hormone replacement therapy use and variations in the risk of breast cancer.
    BJOG, 115(2): 169-75; discussion 175. [Abstract] [Full-text]
19. FoxA1 as a lineage-specific oncogene in luminal type breast cancer.
    Biochem Biophys Res Commun, 365(4): 711-7. [Abstract] [Full-text]
20. Radiologist characteristics associated with interpretive performance of diagnostic mammography.
    J Natl Cancer Inst, 99(24): 1854-63. [Abstract] [Full-text]
21. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    J Natl Cancer Inst, 99(24): 1845-53. [Abstract] [Full-text]
22. Moderators of interventions designed to enhance physical and psychological functioning among younger women with early-stage breast cancer.
    J Clin Oncol, 25(36): 5710-4. [Abstract] [Full-text]
23. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
    J Clin Oncol, 25(36): 5715-22. [Abstract] [Full-text]
24. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    J Clin Oncol, 25(36): 5815-24. [Abstract] [Full-text]
25. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy.
    Nurs Res, 57(1): 51-8. [Abstract] [Full-text]
26. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Cancer Res, 67(24): 11991-9. [Abstract] [Full-text]
27. Oncogenic BARD1 isoforms expressed in gynecological cancers.
    Cancer Res, 67(24): 11876-85. [Abstract] [Full-text]
28. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells.
    Cancer Res, 67(24): 11830-9. [Abstract] [Full-text]
29. Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation.
    Cancer Res, 67(24): 11789-97. [Abstract] [Full-text]
30. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers.
    Cancer Res, 67(24): 11760-8. [Abstract] [Full-text]
31. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.
    Cancer Res, 67(24): 11751-9. [Abstract] [Full-text]
32. A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer.
    Cancer Res, 67(24): 11732-41. [Abstract] [Full-text]
33. SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells.
    Cancer Res, 67(24): 11721-31. [Abstract] [Full-text]
34. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.
    Cancer Res, 67(24): 11612-20. [Abstract] [Full-text]
35. Integrated profiling of basal and luminal breast cancers.
    Cancer Res, 67(24): 11565-75. [Abstract] [Full-text]
36. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.
    Cancer Res, 67(24): 11517-27. [Abstract] [Full-text]
37. RIN1 is a breast tumor suppressor gene.
    Cancer Res, 67(24): 11510-6. [Abstract] [Full-text]
38. Influence of physician and patient characteristics on adherence to breast cancer screening recommendations.
    Eur J Cancer Prev, 17(1): 48-53. [Abstract] [Full-text]
39. Meat consumption, N-acetyl transferase 1 and 2 polymorphism and risk of breast cancer in Danish postmenopausal women.
    Eur J Cancer Prev, 17(1): 39-47. [Abstract] [Full-text]
40. Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma.
    Eur J Cancer Prev, 17(1): 33-8. [Abstract] [Full-text]
41. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
    N Engl J Med, 357(25): 2543-51. [Abstract] [Full-text]
42. Incidence and management of complex fibroadenomas.
    AJR Am J Roentgenol, 190(1): 214-8. [Abstract] [Full-text]
43. Bilateral synchronous breast cancer in an Asian population: mammographic and sonographic characteristics, detection methods, and staging.
    AJR Am J Roentgenol, 190(1): 208-13. [Abstract] [Full-text]
44. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up.
    AJR Am J Roentgenol, 190(1): 202-7. [Abstract] [Full-text]
45. Vbmp: variational Bayesian Multinomial Probit Regression for multi-class classification in R.
    Bioinformatics, 24(1): 135-6. [Abstract] [Full-text]
46. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment.
    Mol Pharmacol, 73(1): 191-202. [Abstract] [Full-text]
47. Osteopontin-c is a selective marker of breast cancer.
    Int J Cancer, 122(4): 889-97. [Abstract] [Full-text]
48. Diagnosis of breast cancer by X-ray diffraction of hair.
    Int J Cancer, 122(4): 847-56. [Abstract] [Full-text]
49. Nijmegen Breakage Syndrome mutations and risk of breast cancer.
    Int J Cancer, 122(4): 802-6. [Abstract] [Full-text]
50. Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts.
    Int J Cancer, 122(4): 816-22. [Abstract] [Full-text]
51. The association between oral contraceptive use and lobular and ductal breast cancer in young women.
    Int J Cancer, 122(4): 936-41. [Abstract] [Full-text]
52. A case-control study on the dietary intake of mushrooms and breast cancer risk among Korean women.
    Int J Cancer, 122(4): 919-23. [Abstract] [Full-text]
53. Computer-aided detection in full-field digital mammography: sensitivity and reproducibility in serial examinations.
    Radiology, 246(1): 71-80. [Abstract] [Full-text]
54. Mammographic, US, and MR imaging phenotypes of familial breast cancer.
    Radiology, 246(1): 58-70. [Abstract] [Full-text]
55. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
    Expert Rev Anticancer Ther, 8(1): 9-13. [Abstract] [Full-text]
56. Meta-analysis of MR imaging in the diagnosis of breast lesions.
    Radiology, 246(1): 116-24. [Abstract] [Full-text]
57. Axillary lymph nodes: US-guided fine-needle aspiration for initial staging of breast cancer--correlation with primary tumor size.
    Radiology, 246(1): 81-9. [Abstract] [Full-text]
58. Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy.
    J Am Coll Surg, 206(1): 76-82. [Abstract] [Full-text]
59. Mortality impact of less-than-standard therapy in older breast cancer patients.
    J Am Coll Surg, 206(1): 66-75. [Abstract] [Full-text]
60. Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up.
    Eur J Surg Oncol, 34(1): 6-12. [Abstract] [Full-text]
61. 'Radioguided occult lesion localisation' (ROLL) for non-palpable breast lesions: a review of the relevant literature.
    Eur J Surg Oncol, 34(1): 1-5. [Abstract] [Full-text]
62. Mucinous breast lesions: diagnostic challenges.
    J Clin Pathol, 61(1): 11-9. [Abstract] [Full-text]
63. Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment.
    Biotechnol Bioeng, 99(2): 442-54. [Abstract] [Full-text]
64. Axillary sentinel lymph node micrometastases with extracapsular extension: a distinct pattern of breast cancer metastasis?
    J Clin Pathol, 61(1): 115-8. [Abstract] [Full-text]
65. Parafibromin expression in breast cancer: a novel marker for prognostication?
    J Clin Pathol, 61(1): 64-7. [Abstract] [Full-text]
66. Antigenicity testing by immunohistochemistry after tissue oxidation.
    J Clin Pathol, 61(1): 79-83. [Abstract] [Full-text]
67. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.
    J Clin Pathol, 61(1): 68-71. [Abstract] [Full-text]
68. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
    J Clin Pathol, 61(1): 89-94. [Abstract] [Full-text]
69. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.
    JAMA, 298(24): 2869-76. [Abstract] [Full-text]
70. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
    Am J Health Syst Pharm, 65(1): 23-8. [Abstract] [Full-text]
71. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    N Engl J Med, 357(26): 2666-76. [Abstract] [Full-text]
72. The emerging landscape of breast cancer susceptibility.
    Nat Genet, 40(1): 17-22. [Abstract] [Full-text]
73. BRCA1--sowing the seeds crooked in the furrow.
    Nat Genet, 40(1): 8-9. [Abstract] [Full-text]
74. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.
    Nat Genet, 40(1): 102-7. [Abstract] [Full-text]
75. Regulation of p53 tetramerization and nuclear export by ARC.
    Proc Natl Acad Sci U S A, 104(52): 20826-31. [Abstract] [Full-text]
76. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
    J Clin Oncol, 26(1): 44-53. [Abstract] [Full-text]
77. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer.
    J Clin Oncol, 26(1): 32-6. [Abstract] [Full-text]
78. BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
    J Clin Oncol, 26(1): 26-31. [Abstract] [Full-text]
79. Advances in the treatment of breast cancer.
    Clin Pharmacol Ther, 83(1): 26-36. [Abstract] [Full-text]
80. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    J Clin Oncol, 26(1): 37-43. [Abstract] [Full-text]
81. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Clin Pharmacol Ther, 83(1): 160-6. [Abstract] [Full-text]
82. Breast metastasis by medullary thyroid carcinoma detected by FDG positron emission tomography.
    Ann Diagn Pathol, 12(1): 67-71. [Abstract] [Full-text]
83. AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.
    Ann Diagn Pathol, 12(1): 33-40. [Abstract] [Full-text]
84. Basaloid carcinoma of the breast: a review of 9 cases, with delineation of a possible clinicopathologic entity.
    Ann Diagn Pathol, 12(1): 4-11. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.